← FDA DRUG APPROVALS

FDA ANDA · ANDA062727

TOTACILLIN-N

Sponsor: GLAXOSMITHKLINE

APPLICATION
ANDA062727
TYPE
ANDA
ORIGINAL APPROVAL
1986-12-19
LATEST ACTION
1994-07-29
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

TOTACILLIN-NDiscontinued
AMPICILLIN SODIUM EQ 2GM BASE/VIAL · INJECTABLE · INJECTION
TOTACILLIN-NDiscontinued
AMPICILLIN SODIUM EQ 1GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

1994-07-29Labeling · Supplement 5AP
1986-12-19OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →